funding probability score
total disclosed funding
last round valuation estimate
disclosed funding rounds
latest round
latest funding stage
next round estimate
development stage
number of investors
number of competitors
monthly web visits
twitter followers
HQ address
EPFL Innovation Park, Lausanne, CH-1015, CHE
Asceneuron will develop effective therapeutics for Alzheimer’s disease and related neurodegenerative diseases such as tauopathies. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.

Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Asceneuron was formed in October 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group. The company comprises a highly experienced management team combining both scientific and drug discovery expertise with a business and fundraising background.

There is much more to this profile.
Log in or sign up for free to see the whole thing.

Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats